サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ワクチンの世界市場：2024年
市場調査レポート
商品コード
1431793

ワクチンの世界市場：2024年

The World Market for Vaccines, 2024
出版日: | 発行: Kalorama Information | ページ情報: 英文 202 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ワクチンの世界市場：2024年
出版日: 2024年02月22日
発行: Kalorama Information
ページ情報: 英文 202 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

ワクチンは、病気に対する長期的あるいは永続的な免疫を提供します。ワクチンは70年以上にわたって予防医学の基礎となっており、特定の病気に対する免疫反応を刺激します。効果的なワクチンが広く普及したことで、多くの致命的な病気がほぼ撲滅され、ワクチン接種は20世紀における最大の公衆衛生の成果のひとつとなっています。

公的な予防接種プログラムのおかげで、ワクチンで予防可能な病気やそれに関連する死亡は、先進国ではまれとなり、世界的に減少しています。天然痘は根絶され、ポリオは南北アメリカで撲滅され、麻疹、風疹、破傷風、ジフテリア、インフルエンザ菌b型などの病気は制圧されています。病気や死亡を防ぐだけでなく、ワクチンは生活の質や生産性を向上させる。疾病の発生を予防し、ヘルスケアコストを削減することで、社会的に大きな利益をもたらしています。

当レポートでは、世界のワクチン市場について調査し、成人および小児用予防ワクチンの最新かつ包括的な分析を提供しています。ワクチンカテゴリー別の市場予測、企業シェアデータ、専門家による市場予測、様々な疾患の予防に使用されるヒト用ワクチンの市場動向も調査しています。特に、既にワクチンで予防可能な疾患について、商業化されているワクチンと開発中のワクチンの両方に焦点を当てています。

目次

第1章 エグゼクティブサマリー

第2章 ワクチンのイントロダクション

  • イントロダクション
  • 略歴：ワクチンの開発
  • 人間の免疫システム
  • ワクチンの作用機序
  • ワクチンの種類
  • 弱毒化（弱化）された生きたウイルス
  • 死滅した（不活化された）ウイルス
  • トキソイドワクチン
  • 遺伝子組み換え/改変ワクチン
  • サブユニットワクチン
  • 結合型ワクチン
  • DNAワクチン
  • メッセンジャーRNAワクチン
  • 組換えベクターワクチン
  • ワクチンの分類
  • ワクチン承認プロセス
  • FDA EUA承認
  • 世界保健機関の認定済みワクチン
  • パンデミック
  • HIN1 2009/2010年のパンデミック
  • コロナウイルスパンデミック
  • エボラ出血熱の流行
  • 製造業奨励金
  • 合成ワクチン
  • 人工知能の開発

第3章 小児予防ワクチン

  • イントロダクション
  • 米国における小児予防接種
  • 小児予防接種率
  • ワクチン送達システムへの課題
  • 推奨される小児予防接種スケジュール
  • 州別予防接種の推奨事項
  • COVID-19の予防接種スケジュール
  • 国連の取り組み
  • 小児ワクチン市場
  • 競合の概要

第4章 成人予防ワクチン

  • イントロダクション
  • 推奨される成人予防接種
  • 世界のインフルエンザ監視プログラム
  • 米国の監視
  • WHOの国際保健規則
  • 成人予防ワクチン市場
  • 市場：成人用非新型コロナウイルスワクチン総売上高の26%を占める
  • インフルエンザ
  • 競合の概要

第5章 ワクチン市場全体

  • ワクチン市場を牽引する動向
  • 市場規模と予測
  • 小児用ワクチン
  • 成人用ワクチン
  • COVID-19市場規模の推定・予測
  • 地域別ワクチン売上高
  • 世界のその他の地域
  • 米国
  • 欧州
  • ワクチン市場の競合企業
  • ワクチン業界のニュース
  • 開発中のワクチン
  • COVID-19ワクチン開発

第6章 企業プロファイル

  • AstraZeneca
  • Bavarian Nordic, A/S
  • Bharat Biotech International Ltd.
  • Bio Farma
  • BioNTech SE
  • CSL Limited/Seqirus
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson/Crucell/Janssen
  • Merck & Co, Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur
  • Serum Institute, Inc.
  • Sinovac Biotech Ltd.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Co, Ltd.
  • Valneva SE
目次
Product Code: 24-012

Vaccines offer long-term or permanent immunity against diseases. They have been a cornerstone of preventive medicine for over 70 years, stimulating an immune response to specific diseases. The widespread adoption of effective vaccines has led to the near-elimination of many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century.

Thanks to public vaccination programs, vaccine-preventable diseases and related deaths are now rare in developed nations and decreasing globally. Smallpox has been eradicated, polio eliminated in the Americas, and diseases like measles, rubella, tetanus, diphtheria, and Haemophilus influenzae type b controlled. Beyond preventing illness and death, vaccines also improve quality of life and productivity. They help prevent disease outbreaks and reduce healthcare costs, providing significant societal benefits.

Kalorama Information's latest report, "The World Market for Vaccines, 2024", offers the most up-to-date and comprehensive analysis of adult and pediatric preventative vaccines. Since the early 2000s, Kalorama has consistently published new editions of The World Market for Vaccines every two years. The report includes market forecasts, company market share data, and expert market estimates for different vaccine categories.

"The World Market for Vaccines, 2024" also examines market trends for human vaccines used to prevent various diseases. It specifically focuses on both commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Additionally, the report discusses selected emerging vaccines in development.

Vaccines covered in the report with sizing and market share include:

  • Combinations (tetanus, pertussis, Hib, Hepatitis, polio)
  • Hepatitis
  • HPV
  • Influenza
  • Meningitis
  • Pandemic vaccines/COVID-19
  • Pneumococcal
  • Rotavirus
  • RSV
  • Shingles
  • Others (travel, endemic, etc.)

The report also examines key companies involved in the market. Companies profiled in the report include:

  • AstraZeneca
  • Bavarian Nordic, A/S
  • Bharat Biotech International Ltd.
  • Bio Farma
  • BioNTech SE
  • CSL Limited/Seqirus
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson/Crucell/Janssen
  • Merck & Co, Inc.
  • Moderna, Inc
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur
  • Serum Institute, Inc.
  • Sinovac Biotech Ltd.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Co, Ltd.
  • Valneva SE

Scope and Methodology

"The World Market for Vaccines, 2024" examines the market for human vaccines used to prevent various types of disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines. It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period. This report does not include therapeutic vaccines such as allergy and cancer vaccines.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the 2023 year and forecasts are provided for 2028. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants' point of view and assess trends and form the basis of the forecasting and competitive analysis.

It should also be noted that due to the very broad scope of this report, with the exception of healthcare spending forecasts, data provided is representative but is not intended to be exhaustive. This includes, for example, tables of vaccines in development and regional economic indicators, etc. Additionally, some statistics, such as those related to venture capital investment, are subject to wide divergences across different sources; where data could not be confidently obtained, trends were discussed rather than absolute numerical values.

Table of Contents

Chapter 1: Executive Summary

  • The Global Vaccines Industry
  • Scope and Methodology
  • Market Estimates and Forecasts
    • Figure 1-1: Global Vaccine Market (Non-COVID Vaccine Market; COVID Vaccine Market), 2023-2028 ($M)
    • Figure 1-2: Regional Non-COVID vs COVID Vaccine Markets, 2018-2028 ($)
  • Competitive Analysis

Chapter 2: Introduction to Vaccines

  • Introduction
    • Table 2-1: Global Reported Cases of Vaccine Preventable Diseases, 2000 vs. 2022
    • Figure 2-1: CDC Infographic: Global Impact of Vaccines in Reducing Vaccine-Preventable Disease Morbidity and Mortality
  • A Brief History: The Development of Vaccines
  • The Human Immune System
  • Vaccine Mechanism of Action
  • Types of Vaccines
  • Attenuated (Weakened) Live Viruses
    • Figure 2-2: Attenuated Virus Production
  • Killed (Inactivated) Viruses
  • Toxoid Vaccines
  • Genetically Engineered/Modified Vaccines
  • Subunit Vaccines
  • Conjugate Vaccines
  • DNA Vaccines
  • Messenger RNA Vaccines
  • Recombinant Vector Vaccines
  • Classification of Vaccines
  • Vaccine Approval Process
    • Figure 2-3: Global Vaccine Sales by Region, 2023
  • FDA EUA Approval
  • World Health Organization Prequalified Vaccines
    • Table 2-3: WHO Prequalified BCG Vaccines
    • Table 2-4: WHO Prequalified Cholera Vaccines
    • Table 2-5: WHO Prequalified Diphtheria-Tetanus Vaccines
    • Table 2-6: WHO Prequalified Diphtheria-Tetanus-Pertussis Vaccines
    • Table 2-7: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hemophilus influenzae type b Vaccines
    • Table 2-8: WHO Prequalified Diphtheria-Tetanus-Pertussis and Hepatitis B Vaccines
    • Table 2-9: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hepatitis B-Hemophilus influenzae type b Vaccines
    • Table 2-10: WHO Prequalified Hemophilus influenzae type b Vaccines
    • Table 2-11: WHO Prequalified Hepatitis A Vaccines
    • Table 2-12: WHO Prequalified Hepatitis B Vaccines
    • Table 2-13: WHO Prequalified Human Papillomavirus Vaccines
    • Table 2-14: WHO Prequalified Influenza Vaccines
    • Table 2-15: WHO Prequalified Japanese Encephalitis Vaccines
    • Table 2-16: WHO Prequalified Measles Vaccines
    • Table 2-17: WHO Prequalified Measles and Rubella Vaccines
    • Table 2-18: WHO Prequalified Measles, Mumps and Rubella Vaccines
    • Table 2-19: WHO Prequalified Meningococcal A Vaccines
    • Table 2-20: WHO Prequalified Pneumococcal Vaccines
    • Table 2-21: WHO Prequalified Polio Vaccines
    • Table 2-22: WHO Prequalified Rabies Vaccines
    • Table 2-23: WHO Prequalified Rotavirus Vaccines
    • Table 2-24: WHO Prequalified Rubella Vaccines
    • Table 2-25: WHO Prequalified Tetanus Toxoid Vaccines
    • Table 2-26: WHO Prequalified Typhoid Vaccines
    • Table 2-27: WHO Prequalified Varicella Vaccine
    • Table 2-28: WHO Prequalified Yellow Fever Vaccines
    • Table 2-29: WHO Prequalified Other Vaccines
  • Pandemics
  • HIN1 Pandemic of 2009/2010
  • Coronavirus Pandemic
    • Figure 2-4: Leading COVID-19 Vaccines: Supplied Dose Estimates
  • Ebola Epidemics
  • Manufacturing Incentives
  • Synthetic Vaccines
  • Artificial Intelligence Development

Chapter 3: Pediatric Preventative Vaccines

  • Introduction
    • Table 3-1: Immunization Rates for Vaccines Recommended by the WHO, 2022
  • Childhood Immunization in the United States
  • Childhood Immunization Rates
  • Challenges to the Vaccine Delivery System
  • Recommended Childhood Immunization Schedule
    • Figure 3-1: CDC Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024
    • Figure 3-2: CDC Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2024
  • State Immunization Recommendations
    • Figure 3-3: Exemptions Permitted for State Childcare and School (Grades PreK-12) Immunization Requirements, United States, March 2023
  • COVID-19 Vaccination Schedule
  • United Nations Initiatives
  • Pediatric Vaccine Markets
    • Table 3-2: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 ($M)
    • Figure 3-4: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 (%)
    • Figure 3-5: Market Share of Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023 (%)
  • Competitive Summary
    • Table 3-3: Major Manufacturers' Shares of the Global Pediatric Preventative Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
    • Figure 3-6: Global Pediatric Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023, (%)

Chapter 4: Adult Preventative Vaccines

  • Introduction
  • Recommended Adult Immunizations
    • Figure 4-1: CDC Recommended Immunization Schedule: Adults, 19 years and over
  • Global Influenza Surveillance Program
  • U.S. Surveillance
    • Table: 4-1: U.S. Influenza Vaccine Effectiveness, 2004-2023 (%)
    • Figure 4-2: U.S. Influenza Vaccine Effectiveness, by Season, 2009-2023, (%)
  • WHO International Health Regulations
  • Adult Preventive Vaccine Markets
    • Table 4-2: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023-2028 ($M)
    • Figure 4-3: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other), 2023-2028 (%)
    • Figure 4-4: Market Share of Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023 (%)
  • Market: Generating 26% of Total Adult Non-COVID Vaccine Sales
    • Figure 4-5: U.S. Seasonal Influenza Vaccination, by Age Group and Season, 2010-2023 (%)
    • Figure 4-6: U.S. Seasonal Influenza Vaccination Coverage and HP 2020 Target - Total Population - Seasons, 2010-2023 (%)
  • Influenza
    • Figure 4-7: Estimated U.S. Flu Burden, by Season 2010-2023
    • Table 4-3: Estimated Number of Influenza Illnesses Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-4: Estimated Number of Influenza Medical Visits Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-5: Estimated Number and Fraction of Influenza Hospitalizations Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-6: Estimated Number of Influenza Deaths Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Figure 4-8: Estimated U.S. Flu Burden Prevented by Vaccination (Deaths, Hospitalizations, Medical Visits, Symptomatic Illness), 2010-2023
    • Table 4-7: WHO Pandemic Classification Schedule
  • Competitive Summary
    • Table 4-8: Major Manufacturers' Shares of the Global Adult Preventative Vaccine Market, by Company (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
    • Figure 4-9: Global Adult Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%)

Chapter 5: Total Vaccines Market

  • Trends Driving the Vaccines Market
    • Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals, 2015-2025
  • Market Size and Forecast
    • Table 5-1: Total Global Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
    • Figure 5-2: Total World Market for Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]),, 2023-2028 (Pediatric, Adult) (SM)
    • Figure 5-3: Total World Vaccine Market, Non-COVID and COVID Vaccine, 2023-2028 ($M)
  • Pediatric Vaccines
  • Adult Vaccines
    • Figure 5-4: Global Preventive Vaccine Market, by Broad Segment (Pediatric, Adult), Trend 2018-2028 ($M)
  • COVID-19 Market Size Estimates and Forecast
    • Table 5-2: Global COVID-19 Vaccine Market Cumulative Value, 2020-2023 ($M)
    • Figure 5-5: Global COVID-19 Vaccine by Unit Volume, Cumulative 2020-2023, Estimated Distribution by Country (Australia, Brazil, Canada, China, European Union, India, Japan, Russia, South Africa, South Korea, United States, Other Countries)
  • Vaccine Sales by Region
  • Rest of World
    • Table 5-3: Total ROW Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • United States
    • Table 5-4: Total U.S. Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • Europe
    • Table 5-5: Total Europe Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • Vaccine Market Competitors
    • Table 5-6: Major Manufacturers' Shares of the Global Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%, $M)
    • Figure 5-6: Global Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%)
  • Vaccine Industry News
  • Vaccines in Development
  • COVID-19 Vaccine Development
    • Figure 5-7: Regional Distribution of COVID-19 Vaccine Development, by Country and Region (Australia, Brazil, Canada, China, France, Indonesia, Japan, Mexico, Middle East, Philippines, Rest of Africa, Rest of Pacific, Rest of Europe, Rest of Latin America, South Africa, South Korea, United Kingdom, United States)
    • Table 5-7: Selected Vaccines in Development, 2023

Chapter 6: Company Profiles

  • AstraZeneca
    • Table 6-1: AstraZeneca Corporate Summary
      • Company Summary
      • Products
  • Bavarian Nordic, A/S
    • Table 6-2: Bavarian Nordic A/S Corporate Summary
      • Company Summary
      • Products
  • Bharat Biotech International Ltd.
    • Table 6-3: Bharat Biotech Corporate Summary
      • Company Summary
      • Products
  • Bio Farma
    • Table 6-4: Bio Farma Corporate Summary
      • Company Summary
      • Products
  • BioNTech SE
    • Table 6-5: BioNTech Corporate Summary
      • Company Summary
      • Products
  • CSL Limited/Seqirus
    • Table 6-6: CSL/Seqirus Corporate Summary
      • Company Summary
      • Products
  • Dynavax Technologies
    • Table 6-7: Dynavax Technologies Corporate Summary
      • Company Summary
      • Products
  • Emergent BioSolutions, Inc.
    • Table 6-8: Emergent BioSolutions Corporate Summary
      • Company Summary
      • Products
  • GlaxoSmithKline, Inc.
    • Table 6-9: GlaxoSmithKline Corporate Summary
      • Company Summary
      • Products
    • Table 6-10: GSK Marketed Vaccines, 2024
  • Inovio Pharmaceuticals, Inc.
    • Table 6-11: Inovio Corporate Summary
      • Company Summary
      • Products
  • Johnson & Johnson/Crucell/Janssen
    • Table 6-12: Johnson & Johnson Corporate Summary
      • Company Summary
      • Products
  • Merck & Co, Inc.
    • Table 6-13: Merck Corporate Summary
      • Company Summary
      • Products
  • Moderna, Inc.
    • Table 6-14: Moderna Corporate Summary
      • Company Summary
      • Products
  • Novavax, Inc.
    • Table 6-15: Novavax Corporate Summary
      • Company Summary
      • Products
  • Pfizer, Inc.
    • Table 6-16: Pfizer Corporate Summary
      • Company Summary
      • Products
  • Sanofi Pasteur
    • Table 6-17: Sanofi Pasteur Corporate Summary
      • Company Summary
      • Products
  • Serum Institute, Inc.
    • Table 6-18: Serum Institute of India Corporate Summary
      • Company Summary
      • Products
  • Sinovac Biotech Ltd.
    • Table 6-19: Sinovac Biotech Corporate Summary
      • Company Summary
      • Products
  • Soligenix, Inc.
    • Table 6-20: Soligenix Corporate Summary
      • Company Summary
      • Products
  • Takeda Pharmaceutical Co, Ltd.
    • Table 6-21: Takeda Pharmaceutical Corporate Summary
      • Company Summary
      • Products
  • Valneva SE
    • Table 6-22: Valneva Corporate Summary
      • Company Summary
      • Products